



## RSV, ADV, FLU A/B & COVID-19 Rapid Antigen Combo Test

A Rapid test for the qualitative detection of novel coronavirus antigens, influenza A&B virus, respiratory syncytical virus, adenovirus in nasal swab.

For self-testing use.

REF:K881416D

English


### QR CODE INSERT

Scan the QR code for information on how to use the RSV, ADV, FLU A/B & COVID-19 Rapid Antigen Combo Test.



**Doncaster Australia Pty Ltd T/A Mootilda Australia**  
**Customer Support Number: 1300880878**  
**Address: 135 Bamfield Road Heidelberg Heights, Victoria 3081**  
**Hours: 9am-7pm AEST/9am-8pm AEDT, 7 days per week**  
**Email: [Info@mootildarealytech.com.au](mailto:Info@mootildarealytech.com.au)**  
**Website: [www.mootildarealytech.com.au](http://www.mootildarealytech.com.au)**

### MATERIALS PROVIDED



Test device



Package Insert



Extraction Tube with buffer



Biohazard Specimen Bag

Sterilized Swab (The information about the swab can be found on its packaging.)



Tube stand(The 25 tests/kit package contains the tube stand,the 1 test/kit , 2 tests/kit and 5 tests/kit package use the test box itself as tube stand.)

Materials required but not provided

Timer

### TEST PROCEDURE

#### Step 1

Wash or clean your hands and make sure they are dry before starting the test.




#### Step 2

Read the instruction for use carefully




#### Step 3

Take out one Extraction Tube (containing buffer), pull off the sealed aluminum foil on the extraction tube. Place extraction tube into tube stand or the box tube stand.



#### Step 4

Unpack the swab. **Caution: Do not touch swab tip when handling the swab.**




#### Step 5

Tilt your head back slightly. Insert the swab about 2 cm - at least with the entire soft swab tip - into the left nostril. Gently rotate the swab at least five times against the nasal wall.



#### Step 6

Insert the same swab about 2 cm - at least with the entire soft swab tip - into the right nostril. Again, gently rotate the swab at least five times against the nasal wall. Remove the swab from the second nostril. **Caution: If the swab stick breaks during specimen collection, please use a new swab.**




#### Step 7

Dip the soft swab tip into the liquid. Rotate the swab for at least 15 seconds while pressing the tip against the inside of the tube to dissolve the specimen in the liquid.



#### Step 8

Remove the swab from the extraction tube by squeezing the sides of the tube together and pulling the swab out to ensure most of the buffer remains in the tube. Discard swab in biohazard specimen bag.



#### Step 9

Screw on and tighten the nozzle onto the extraction tube.



#### Step 10

Shake the extraction tube for 30 seconds to mix the specimen and the sample extraction buffer.




#### Step 11

Open the foil pouch and take out the test cassette. Place the test cassette on a flat, clean surface. **CAUTION: Perform the test within 60 minutes after the foil pouch is opened.**



#### Step 12

Add 3 drops of the solution from the specimen collection tube to each sample well of the test cassette.



#### Step 13

Set timer for 15 minutes. **CAUTION: Do not read the result before hand, even if a line has already appeared at control region C. The test results will be invalid if read after 20 minutes.**



#### Step 14

Please dispose of the test materials in a biohazard specimen bag with the household refuse. If there are local regulations, please follow them.



#### Step 15

Wash hands thoroughly after test completion.



### INTERPRETATION OF RESULTS

**POSITIVE SARS-Cov-2:** Two red lines appear. One red line appears in the control region(C), and one red line in the test region(Cov).

**POSITIVE Influenza A:** Two distinct colored lines appear. One colored line should be in the control region (C) and another colored line should be in the Influenza A region (A). A positive result in the Influenza A region indicates that Influenza A antigen was detected in the sample.

**POSITIVE Influenza B:** Two distinct colored lines appear. One colored line should be in the control region (C) and another colored line should be in the Influenza B region (B). A positive result in the Influenza B region indicates that Influenza B antigen was detected in the sample.

**POSITIVE Influenza A and Influenza B:** Three distinct colored lines appear. One colored line should be in the control region (C) and two colored line should be in the Influenza A region (A) and Influenza B region (B). A positive result in the Influenza A region and Influenza B region indicates that Influenza A antigen and Influenza B antigen were detected in the sample.

**POSITIVE RSV:** Two red lines appear. One red line appears in the control region(C), and one red line in the test region(Rsv). The shade of color may vary, but it should be considered positive whenever there is even a faint line.

**POSITIVE ADV:** Two distinct red lines appear. One red line should be in the control line region(C) and another apparent red line should be in the test line region(Adv)

**\*NOTE: The shade of color may vary, but it should be considered positive whenever there is even a faint line.**

### What To Do if a Positive Result is Obtained


If you have a Covid-19 POSITIVE result, staying at home protects the people in your community and you should not visit high-risk settings like hospitals and aged and disability care settings. If you feel unwell or need COVID-19 advice for someone in your care, talk with your health provider, or speak to a nurse by calling the healthdirect helpline on 1800 022 222. If you develop symptoms such as severe shortness of breath or chest pain, call triple zero (000) immediately. Tell the call handler and the paramedics on arrival if you have COVID-19.

If you have a Influenza, RSV or ADV POSITIVE result, individuals are advised to consult a medical practitioner for follow-up clinical care.


**NEGATIVE:** Only one red line appears in the control region(C), and no line in the test region(B/A/Cov/Adv/Rsv). If symptoms persist advice to conduct repeat testing and seek professional medical advice.

**INVALID:** No red line appears in the control region(C). The test is invalid even if there is a line on test region(B/A/Cov/Adv/Rsv). Insufficient sample volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the test procedure and repeat the test using a new test device. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

### SARS-Cov-2 & Influenza A&B



### Rsv & Adv



## INTENDED USE

RSV, ADV, FLU A/B & COVID-19 Rapid Antigen Combo Test is an in vitro diagnostic test for the qualitative detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein antigen, Influenza A&B (Flu A&B) nucleoprotein antigen, Respiratory Syncytial Virus (RSV) F antigen and Adenovirus (ADV) hexon protein in nasal swab within 7 days of onset of symptoms, as an aid for diagnosis of COVID-19, within 4 days of onset of symptoms, as an aid for diagnosis of Influenza A/B, within 6 days of onset of symptoms, as an aid for diagnosis of RSV within 6 days of onset of symptoms, and as an aid for diagnosis of ADV, using the rapid immunochromatographic method. This kit is intended for layperson's home use in a non-laboratory environment. (This product is not intended for children under three years old.)

## PRINCIPLE

The RSV, Adv, Flu A/B & Covid-19 Rapid Antigen Combo Test is a lateral flow immunoassay based on the principle of the double antibody sandwich technique. A monoclonal Covid-19/Flu A&B/RSV/Adv antibody conjugated with colored microparticles and sprayed onto the conjugation pad is used as a detector. During the test, the Covid-19/Flu A&B/RSV/Adv antigen in the sample interacts with the Covid-19/Flu A&B/RSV/Adv antibody conjugated with colored microparticles, creating an antigen-antibody labeled complex. This complex migrates on the membrane by capillary action up to the Test line where it is captured by the pre-coated monoclonal Covid-19/Flu A&B/RSV/Adv antibodies. A colored test line (B/A/Cov/Adv/Rsv) would be visible in the each result window if Covid-19/Flu A&B/RSV/Adv antigens are present in the sample. The absence of the T line indicates a negative result. The control line (C) is for procedural control and should appear whenever the test procedure is being performed properly.

## PRECAUTIONS

- For in vitro diagnostic use only.
- Ensure foil pouch containing test device is not damaged before opening for use.
- Perform the test at room temperature 15 to 30°C.
- Do not substitute the swab and sample extraction buffer provided in this kit with components from other kits.
- Place the soft tip of the swab into the nostril.
- Strictly follow the operating instructions.
- The samples should be tested immediately after collection.
- Children aged 3 to 15 years old should have their samples collected and tested by an adult. Do not use the test for anyone under 3 years old.
- The test can only be used once.
- Please dispose of the used test materials in the medical waste bin.
- Test kit solutions should only be used as directed; do not ingest; do not dip the swab into provided solution or other liquid before inserting the swab into the nose; avoid contact with skin and eyes; keep out of the reach of children and pets before and after use.
- If the extraction buffer comes in contact with the skin or eyes, flush with plenty of water.

## STORAGE AND STABILITY

Store the Rapid Test Cassette at room temperature or refrigerated (2-30°C). Do not freeze. All reagents are stable until the expiration dates marked on their outer packaging and buffer vial. Test the sample within an hour after opening with RH<80%.

## LIMITATIONS

- False positive results may occur, particularly in individuals without COVID-19 symptoms and/or individuals who live in areas with low numbers of Covid-19 infections and without known exposure to COVID-19.
- The test is an acute-phase screening test for qualitative detection. Sample collected may contain antigen concentration below the reagent's sensitivity threshold, so a negative test result does not exclude infection.
- The test detects viable and non-viable Influenza A and/or B virus and/or novel coronavirus antigen and/or RSV virus and/or ADV virus . Test performance depends on antigen load in the sample and may not correlate with cell culture performed on the same sample. A positive test does not rule out the possibility that other pathogens may be present, therefore, the results must be compared with all other available clinical and laboratory information to make an accurate diagnosis.
- Performance of the test has not been established for monitoring antiviral treatment of novel coronavirus. Positive test results do not rule out co-infections with other pathogens.
- The negative test results for novel coronavirus are not intended to rule in other coronavirus infection except the SARS-Cov-2.
- A negative result does not rule out infection with another type of respiratory virus.
- A negative result may occur if the concentration of antigen in a specimen is below the detection limit of the test or if the specimen was collected or transported improperly, therefore a negative test result does not eliminate the possibility infection.
- Negative results may not mean that a person is not infectious and if symptoms persist, please seek medical advice.
- Recommend repeat testing within 1-3 days if there is an ongoing suspicion of infection, being in a high risk setting or where there is an occupational risk or other requirement.
- Risk of false-negative results for COVID-19, particularly if testing is not performed within the first 7 days of symptom onset.
- Risk of false-negative results for Influenza A/B, particularly if testing is not performed within the first 4 days of symptom onset.
- The tests are less reliable in the later phase of infection and in asymptomatic individuals.
- A positive result cannot necessarily determine whether a person is infectious.

## SAFETY INFORMATION

- Please dispose of the test materials in a closed plastic bag with the household refuse.
- Test kit buffer should only be used as directed; do not ingest.
- Do not dip the swab into provided solution or other liquid before inserting the swab into the nose.
- The buffer should avoid contact with skin and eyes.
- The buffer should keep out of the reach of children and pets at all times before taking samples and after use.
- If the extraction buffer comes in contact with the skin or eyes, flush with plenty of water. If irritation

persists, seek medical advice from a doctor or your local medical centre.

## PERFORMANCE CHARACTERISTICS

### Clinical Evaluation

Using RSV, ADV, FLU A/B & COVID-19 Rapid Antigen Combo Test by professional was compared to the RT-PCR kit. The sensitivity is 95.45% (105/110 known confirmed positive) for Covid-19 and 97.80% (88/90 known confirmed positive) for Flu A and 97.50% (39/40 known confirmed positive) for Flu B and 93.55% (58/62 known confirmed positive) for RSV and 98.33% (59/60 known confirmed positive) for Adv. The specificity is > 99.9% (480/480 known confirmed negatives) for Covid-19 and > 99.9% (500/500 known confirmed negatives) for Flu A and > 99.9% (550/550 known confirmed negatives) for Flu B and >99.9%(528/528 known confirmed negatives) for RSV And >99.9%(530/530 known confirmed negatives) for Adv.

### Usability Study

Using RSV, ADV, FLU A/B & COVID-19 Rapid Antigen Combo Test by layperson was compared to the RT-PCR kit. The sensitivity is 97.83% (90/92) for Covid-19 , 97.73% (86/88) for Flu A, 97.65% (83/85) for Flu B, 98.75% (79/80) for RSV, >99.99% (75/75) for Adv, the specificity is >99.99% (408/408) for Covid-19, > 99.99% (412/412) for Flu A, > 99.99% (415/415) for Flu B, > 99.99% (420/420) for RSV and > 99.99%(425/425) for Adv.

### Variants Information

The following SARS-CoV-2 variants can be detected with RSV, ADV, FLU A/B & COVID-19 Rapid Antigen Combo Test:Delta and Omicron.

The following Influenza strains can be detected with RSV, ADV, FLU A/B & COVID-19 Rapid Antigen Combo Test :A/Darwin/6/2021, A/Darwin/9/2021, A/Victoria/2570/2019, Hong Kong/2671/2019, A/Guangdong-Maonan/SWL1536/2019, A/Brisbane/02/2018, A/Michigan/45/2015, A/Victoria/361/2011, A/Texas/50/2012, A/California/7/2009, A/SouthAustralia/34/2019, A/Switzerland/8060/2017, A/Singapore/INF1MH-16-0019/2016, A/Sydney/5/2021, B/Phuket/3073/2013(B/Yamagata lineage), B/Austria/1359417/202 (B/Victoria lineage), B/Washington/02/2019(B/Victoria lineage), B/Colorado/06/2017(B/Victoria/2/87 lineage), B/Massachusetts/2/2012.

The following RSV strains can be detected with RSV, ADV, FLU A/B & COVID-19 Rapid Antigen Combo Test: A-2,Long,9320,Washington,B-1 wild type.

The following Adv strains can be detected with RSV, ADV, FLU A/B & COVID-19 Rapid Antigen Combo Test: Adv Type 1, Type 2, Type 3, Type4, Type 5, Type 6, Type 7.

### Limit of Detection (LOD)

The Limit of Detection (LoD) of the RSV, ADV, FLU A/B & COVID-19 Rapid Antigen Combo Test is  $6.25 \times 10^2$  TCID<sub>50</sub>/ml for Covid-19,  $1.0 \times 10^2$  TCID<sub>50</sub>/ml for Flu A(H1N1),  $1.0 \times 10^3$  TCID<sub>50</sub>/ml for Flu B (B-Victoria Lineage),  $2.4 \times 10^2$  TCID<sub>50</sub>/ml for RSV (A-2),  $1.8 \times 10^2$  TCID<sub>50</sub>/ml for Adv (Ad3).

### Cross Reaction












The Cross-reactive study results shows that the SARS-coronavirus(or SARS-CoV-1) affects the test results for SARS-CoV-2. The Cross reactive study results shows that no cross-reactivity was observed with the other microorganisms and analytes tested (MERS-coronavirus, Legionella pneumophila(Bloomington-2, Los Angeles-1, 82A3105) , Mycobacterium tuberculosis(K, Erdman, HN878, CDC1551,H37Rv), Streptococcus pneumoniae(4752-98 [Maryland (D1)6B-17], 178 [Poland 23F-16], 262 [CIP 104340], Slovakia 14-10 [29055]), Streptococcus pyrogens(Typing strain T1,[NCIB 11841, SF 130]), Mycoplasma pneumoniae(Mutant 22, FH strain of Eaton Agent [NCTC10119], 36M129-B7), Coronavirus(229E, OC43, NL63, HKU1), Human Metapneumovirus (hMPV) 3 Type B1(Peru2-2002), Human Metapneumovirus (hMPV) 16 Type A1(IA10-2003), Parainfluenza virus(Type 1, Type 2, Type 3, Type 4), Rhinovirus A16, candida albicans(CICC 1965), pseudomonas aeruginosa(ATCC9027), staphylococcus epidermis(ATCC 14990), staphylococcus salivarius(ATCC 25975), Enteroviruse(EV68, EV71), Chlamydiapneumoniae(VR2282), haemophilus influenzae(ATCC9006), bordetella pertussis(ATCC9340), Pneumocystis jirovecii(M167-6)).The test kit can detect Covid-19, Flu A /B ,RSV and Adv in presence of co-infection.

### Interfering Substances

**When tested using the RSV, ADV, FLU A/B & COVID-19 Rapid Antigen Combo Test, there was no interference between the device reagents and the Potential interference substances listed in below that would create false positive or negative results:**

Mucin; Whole Blood; Biotin; Neo-Synephrine (Phenylephrine); Afrin Nasal Spray (Oxymetazoline); Saline Nasal Spray; Homeopathic; Sodium Cromoglycate; Olopatadine Hydrochloride; Zanamivir; Oseltamivir; Artemether-lumefantrine; Doxycycline hyclate; Quinine; Lamivudine; Ribavirin; Daclatasvir; Acetaminophen; Staphylococcus aureus; Acetylsalicylic acid; Ibuprofen; Mupirocin; Tobramycin; Erythromycin; Ciprofloxacin; Ceftriaxone; Meropenem; Tobramycin; Histamine Hydrochloride;Peramivir; Flunisolide; Budesonide; Fluticasone; Lopinavir; Ritonavir; Abidor; Pooled human nasal wash; HAMA.

## SYMBOL

Symbol	Meaning	Symbol	Meaning
	In vitro diagnostic medical device		Storage temperature limit
	Manufacturer		Contains sufficient for <n> tests
	Date of Manufacture		Use-by date
	Do not re-use		Consult instructions for use or consult electronic instructions for use
	Batch code		Do not use if package is damaged and consult instructions for use
	Catalogue number		

### Report Performance or Usability Issues:

You can contact the Therapeutic Goods Administration (TGA) to report poor performance or usability issues via online, email [iris@tga.gov.au](mailto:iris@tga.gov.au) or call 1800 809 361.



**Hangzhou Realy Tech Co., Ltd.**

#2 Building, No. 763, Yuansha Village, Xinjie Street, Xiaoshan District, 311200 Hangzhou City, Zhejiang Province, PEOPLE'S REPUBLIC OF CHINA  
**Website: [www.realytech.com](http://www.realytech.com)**

Number:1100146601  
Version: 1.0  
Effective Date:2025-01-22

**Doncaster Australia Pty Ltd T/A Mootilda Australia**  
**Customer Support Number: 1300880878**  
**Address: 135 Bamfield Road Heidelberg Heights, Victoria 3081**  
**Hours: 9am-7pm AEST/9am-8pm AEDT, 7 days per week**  
**Email: [Info@mootildarealytech.com.au](mailto:Info@mootildarealytech.com.au)**  
**Website:[www.mootildarealytech.com.au](http://www.mootildarealytech.com.au)**